Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/30/24
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 07/09/24
End: 12/31/30
Due: 12/31/31
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy | NCT06263153 | Yuanquan Yang | user2@example.com | None | 2024-12-30 | 2026-12-31 | 2027-12-31 | - | - | 2025-07-14 |
| Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients with Advanced Cancer, CIRES Trial | NCT06470971 | Yuanquan Yang | user2@example.com | None | 2024-07-09 | 2030-12-31 | 2031-12-31 | - | - | 2025-07-14 |